Actinium Stock Soars 13.29% on Key Supply Agreement

On March 26, 2025, Actinium's stock price surged by 13.29% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.

Actinium Pharmaceuticals has secured a crucial supply agreement with Eckert & Ziegler for Actinium-225 (Ac-225), a vital radioisotope for targeted cancer therapies. This agreement is pivotal for the development of Actinium's lead product, Actimab-A, which is being advanced into a pivotal Phase 2/3 trial for relapsed/refractory acute myeloid leukemia (AML) and a Phase 1 trial in frontline settings with the National Cancer Institute (NCI).

The strategic partnership with Eckert & Ziegler addresses a critical operational challenge in radiopharmaceutical development by ensuring a reliable supply of Ac-225, which is currently facing a global shortage. This agreement not only stabilizes the supply chain for Actinium's core therapeutic platform but also significantly reduces the execution risk for their clinical initiatives.

Actinium is also expanding the application of Actimab-A to solid tumors, combining it with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO for trials in head and neck squamous carcinoma and non-small cell lung cancer. This diversification of Actimab-A's therapeutic potential further enhances the company's growth prospects and market position.